Cystinicline: A New Hope for Smokers?
Episode Overview
Cystinicline shows promise as a new smoking cessation treatment. Opioid use disorder remains a challenge in nursing homes. Social media addiction impacts mental health and focus. AI-driven misinformation raises ethical concerns. Older adults face significant barriers to substance use treatment.
"For about four to five people who try this medication, one will be able to quit smoking."
Ever wondered how a medication from the 1960s is making waves in the smoking cessation world today? Episode 69 of the Addiction Medicine Journal Club explores cystinicline, a promising treatment for quitting smoking. Dr. John Keenan and Dr. Sonya Del Tredici break down the ORCA Phase 3 Replication Randomized Clinical Trial, revealing how this old-school medication could be a game-changer for smokers.
With smoking cessation success rates not exactly setting the world on fire, cystinicline might just be the breath of fresh air needed. The hosts also dive into other hot topics like opioid use disorder in nursing homes and the compulsive scrolling habits spurred by TikTok. A recent lawsuit in South Carolina highlights the discrimination faced by older adults with substance use disorders, sparking discussions on the need for better access to medical services.
On a lighter note, the hosts share their struggles with social media addiction, proving that even addiction medicine experts aren't immune to the lure of endless scrolling. So, whether you're curious about new treatments or pondering the societal impact of smartphone addiction, this episode offers a mix of serious insights and relatable anecdotes. Are you ready to learn about cystinicline's potential to kick smoking to the curb?